Ani pharmaceuticals reports third quarter 2021 results

Baudette, minn.--(business wire)--ani pharmaceuticals, inc. (ani or the company) (nasdaq: anip) today announced business highlights and financial results for the three months ended september 30, 2021. third quarter and recent business highlights: the u.s. food and drug administration (fda) approved the company's supplemental new drug application (snda) for purified cortrophin™ gel (repository corticotropin injection usp) (cortrophin gel) for the treatment of certain chronic autoimmune disorders
ANIP Ratings Summary
ANIP Quant Ranking